Key Highlights:

Physicians and patients are overwhelmed with the number and variety of digital health technologies coming to market.
Marketing authorizations by the U.S. FDA and its European counterparts normally bear signal effects: a product has been tested in a way that it is safe and efficacious for its intended purpose.
This is currently not the case for digital health technologies (DHTs) given their characteristics, changes in actors and use contexts and lack of specific regulation in regard to those challenges.
The consequent regulatory gap, i.e. the lack of effective regulation of such technologies, poses a threat to patient-...

Join eMHIC to

Our Knowledge Bank is available to eMHIC Members, and filled with exclusive articles on thought provoking and ground breaking subject matters. We are continually updating it in line with the rapidly evolving health industry, and the ever-changing requirements of mental health practices as we navigate the pandemic as a planet. To access these articles in full, please login or join us.